New Gene Discovery A Potential Drug Target For Tuberculosis

New Gene Discovery A Potential Drug Target For Tuberculosis
Mycobacterium tuberculosis, shown in red, is known to propagate
in macrophage cells (left), but loses that ability when MenJ is
knocked out (right). (Credit: American Chemical Society)
The U.S. Food and Drug Administration recently approved the first new drug to fight tuberculosis (TB) in more than 40 years, but treatment still takes six months, 200 pills and leaves 40 percent of patients uncured. Thus, new targets are needed. Today in ACS Central Science, researchers report they have identified one such target - a gene that allows the disease to camp out in human immune cells, and is thus essential for the organism's proliferation.
 
TB kills about 1.3 million people around the world every year. The microorganism that causes the disease, Mycobacterium tuberculosis, can hide from the immune system in the macrophage cells of the lungs and go undetected for years. Drugs that target M. tuberculosis generally target cell-wall and protein synthesis, like most antibiotics. However, since TB remains in a latent phase for many patients, and these treatments target growth processes, they are often ineffective at eliminating the bacteria. Other universal processes may provide better targets for rapid treatment of the disease. One such essential process is electron transport, which powers all life forms by shuttling electrons between key protein complexes. In bacteria, the only electron chauffeur is a molecule called menaquinone (MK) that has species-specific variations in its structure. Researchers set out to determine how MK might be involved in TB virulence.
 
First, the researchers compared genes in TB with those known to modify the electron shuttles for other organisms, leading them to a gene they called MenJ. This gene was shown to produce the specific form of MK unique to TB. To test MenJ's function, the researchers created a mutant strain of M. tuberculosis without the MenJ gene and found that while this deletion did not kill the bacteria outright, it lost its ability to infect human macrophage cells in less than four days. The researchers say they have identified a novel virulence factor that could be ripe for drug development.
 
Based on material originally posted by American Chemical Society.